Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ciclesonide
Drug ID BADD_D00460
Description Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indications and Usage For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Marketing Status approved; investigational
ATC Code R01AD13; R03BA08
DrugBank ID DB01410
KEGG ID D01703
MeSH ID C120481
PubChem ID 6918155
TTD Drug ID D0K7HU
NDC Product Code 70515-711; 53104-7633; 70515-712; 70515-701; 64918-1900; 24002-0016; 64918-1112; 70515-737
UNII S59502J185
Synonyms ciclesonide | (R)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate | Alvesco | Omnaris
Chemical Information
Molecular Formula C32H44O7
CAS Registry Number 126544-47-6
SMILES CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haemoglobin13.01.05.018--Not Available
Hallucination, visual19.10.04.0070.000834%Not Available
Headache17.14.01.0010.001971%
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.003--Not Available
Hypersensitivity10.01.03.0030.000947%
Hypertension24.08.02.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Insomnia19.02.01.002; 17.15.03.0020.001023%
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Laboratory test abnormal13.18.01.001--Not Available
Laryngeal pain22.12.03.010--
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.005--Not Available
Malaise08.01.01.0030.000568%
Malignant melanoma23.08.01.001; 16.03.01.0010.000379%Not Available
Menstrual disorder21.01.01.0040.000379%Not Available
Middle insomnia17.15.03.003; 19.02.01.003--Not Available
Multiple fractures12.04.02.009; 15.08.02.005--Not Available
Myalgia15.05.02.0010.000834%
Nasal congestion22.04.04.001--
Nasal dryness22.04.03.002--Not Available
Nasal septum disorder22.04.03.015--Not Available
Nasal septum perforation22.04.03.003--Not Available
Nasal ulcer22.04.03.011--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages